Multicentric reticulohistiocytosis

Is itchy skin (pruritus) known to be associated with multicentric reticulohistiocytosis?

Yes. It has been estimated that about 1 in 3 people with multicentric reticulohistiocytosis report that they experience pruritus.

Last updated on 05-01-20

What is the prognosis for individuals with multicentric reticulohistiocytosis?

After an average course of 8 years, patients often go into remission (a state where symptoms have subsided). The disease can cause considerable morbidity (disability as a result of the disease), mainly related to the occurrence of severe arthritis. The arthritis can come and go, but it can be very severe in about 45% of cases. If the patient has an associated cancer, the prognosis relates to that of the specific cancer.

Last updated on 05-01-20

How might multicentric reticulohistiocytosis be treated?

Dermatologists and rheumatologists are often the types of specialists that oversee the treatment of patients with multicentric reticulohistiocytosis. Although no specific therapy has consistently been shown to improve multicentric reticulohistiocytosis, many different drugs have been used. For instance, therapy with non-steroidal anti-inflammatory agents (e.g., aspirin or ibuprofen) may help the arthritis. Systemic corticosteroids and/or cytotoxic agents, particularly cyclophosphamide, chlorambucil, or methotrexate, may affect the inflammatory response, prevent further joint destruction, and cause skin lesions to regress. Antimalarials (e.g., hydroxychloroquine and mefloquine) have also been used. Alendronate and other bisphosphonates have been reported to be effective in at least one patient and etanercept and infliximab have been effective in some.

Last updated on 05-01-20

How might itchiness (pruritus) associated with multicentric reticulohistiocytosis be treated?

When severe, pruritus can adversly affect daily living. Managing this symptom is important and may require long-term therapy. While the optimal treatment for multicentric reticulohistiocytosis associated pruritus is not currently known, you may find the following article to be a helpful resource. This article reviews current approaches to treating pruritus associated with paraneoplastic skin diseases. It explores the use of selective serotonin reuptake inhibitors, selective neuroepinephrine re-uptake inhibitors, ultraviolet therapy, and combination therapies for treatment of chronic itch. We recommend that you review this article with your healthcare provider.

Yosipovitch G. Chronic pruritus: a paraneoplastic sign. Dermatol Ther. 2010 Nov-Dec;23(6):590-6. Click on the title to view the full-text article.

Last updated on 05-01-20

Name: Histiocytosis Association 332 North Broadway
Pitman, NJ, 08071 , United States
Phone: +1-856-589-6606 Toll Free: 1-800-548-2758 (from US and Canada) Fax : +1-856-589-6614 Email: info@histio.org Url: https://www.histio.org/
Name: Histiocytosis Association of Canada 41 Milverton Close Waterdown, ON
L8B 0A9
Canada
Email: info@histio.ca Url: https://histiocytosis.ca/
Name: Arthritis Foundation 1355 Peachtree St. NE 6th Floor
Atlanta, GA, 30309, United States
Phone: +1-404-872-7100 Toll Free: 1-844-571-HELP (4357) Url: https://www.arthritis.org

Connect with other users with Multicentric reticulohistiocytosis on the RareGuru app

Do you have information about a disease, disorder, or syndrome? Want to suggest a symptom?
Please send suggestions to RareGuru!

The RareGuru disease database is regularly updated using data generously provided by GARD, the United States Genetic and Rare Disease Information Center.

People Using the App

Join the RareGuru Community

To connect, share, empower and heal today.

People Using the App